Profile - To The Moon

iawang

challenge accepted!

Posts · 18Posts · 18
Following · 0Following · 0
Followers · 0Followers · 0

- iawangiawang
  ·2021-07-13
  Woot woot lalamove!
  Sorry, this post has been deleted
  2.46K 1
  4
  Share
  Report
- iawangiawang
  ·2021-07-06
  Nothing to worry!
  Sorry, this post has been deleted
  2.19K 1
  7
  Share
  Report
- iawangiawang
  ·2021-07-05
  Share to poorer nations
  Israel negotiating Pfizer surplus with other countries, official says
  JERUSALEM, July 4 (Reuters) - Israel is in talks with other countries about a deal to unload its sur
  Israel negotiating Pfizer surplus with other countries, official says
  1.73K 1
  4
  Share
  Report
- iawangiawang
  ·2021-07-04
  Go go go go go!!!
  U.S. stocks sweep to fresh highs after strong jobs report
  Stocks rose Friday to record levels as investors digested a key print on the U.S. labor market recovery, which pointed to a faster pace of payroll gains than expected.The S&P 500 set another record high, kicking off the first sessions of the third quarter on a high note. The blue-chip index logged a seventh straight day of gains in its longest winning streak since August 2020. The Nasdaq also hit all-time intraday and closing highs, and the Dow gained to set its first record high since May 7. Sh
  U.S. stocks sweep to fresh highs after strong jobs report
  2.00K 1
  4
  Share
  Report
- iawangiawang
  ·2021-06-30
  Commenting now
  These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday
  The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The ind
  These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday
  1.82K 1
  1
  Share
  Report
- iawangiawang
  ·2021-06-29
  Oops hello there
  Sorry, this post has been deleted
  2.16K 1
  7
  Share
  Report
- iawangiawang
  ·2021-06-28
  Gooooogle!!!
  Sorry, this post has been deleted
  1.90K Comment
  3
  Share
  Report
- iawangiawang
  ·2021-06-25
  Here is a comment
  Sorry, this post has been deleted
  2.33K 1
  5
  Share
  Report
- iawangiawang
  ·2021-06-24
  Strong!!! Comment!!!
  Sorry, this post has been deleted
  1.87K 1
  7
  Share
  Report
- iawangiawang
  ·2021-06-21
  Test comment here
  Sorry, this post has been deleted
  1.58K Comment
  Like
  Share
  Report
No followers yet

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3574379344635374","uuid":"3574379344635374","gmtCreate":1611286175700,"gmtModify":1708866278236,"name":"iawang","pinyin":"iawang","introduction":"","introductionEn":"","signature":"challenge accepted!","avatar":"https://community-static.tradeup.com/news/090ab974c3086142d05263cd704a81b6","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":6,"tweetSize":18,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.04","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.11","exceedPercentage":"60.30%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.11","exceedPercentage":"60.71%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":142791868,"gmtCreate":1626174512754,"gmtModify":1703754799333,"author":{"id":"3574379344635374","authorId":"3574379344635374","name":"iawang","avatar":"https://community-static.tradeup.com/news/090ab974c3086142d05263cd704a81b6","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3574379344635374","idStr":"3574379344635374"},"themes":[],"htmlText":"Woot woot lalamove!","listText":"Woot woot lalamove!","text":"Woot woot lalamove!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/142791868","repostId":"1116631822","repostType":4,"isVote":1,"tweetType":1,"viewCount":2464,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154261225,"gmtCreate":1625530289667,"gmtModify":1703743026673,"author":{"id":"3574379344635374","authorId":"3574379344635374","name":"iawang","avatar":"https://community-static.tradeup.com/news/090ab974c3086142d05263cd704a81b6","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3574379344635374","idStr":"3574379344635374"},"themes":[],"htmlText":"Nothing to worry!","listText":"Nothing to worry!","text":"Nothing to worry!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/154261225","repostId":"1101802021","repostType":4,"isVote":1,"tweetType":1,"viewCount":2194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":155481253,"gmtCreate":1625448915072,"gmtModify":1703741872602,"author":{"id":"3574379344635374","authorId":"3574379344635374","name":"iawang","avatar":"https://community-static.tradeup.com/news/090ab974c3086142d05263cd704a81b6","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3574379344635374","idStr":"3574379344635374"},"themes":[],"htmlText":"Share to poorer nations","listText":"Share to poorer nations","text":"Share to poorer nations","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/155481253","repostId":"2148388731","repostType":4,"repost":{"id":"2148388731","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1625445203,"share":"https://ttm.financial/m/news/2148388731?lang=&edition=fundamental","pubTime":"2021-07-05 08:33","market":"us","language":"en","title":"Israel negotiating Pfizer surplus with other countries, official says","url":"https://stock-news.laohu8.com/highlight/detail?id=2148388731","media":"Reuters","summary":"JERUSALEM, July 4 (Reuters) - Israel is in talks with other countries about a deal to unload its sur","content":"<p>JERUSALEM, July 4 (Reuters) - Israel is in talks with other countries about a deal to unload its surplus of Pfizer/BioNtech</p>\n<p>COVID-19 vaccines, doses of which are due to expire by the end of the month, a health ministry official said on Sunday.</p>\n<p>Hezi Levi, the ministry's director-general, did not provide details about the number of doses Israel was looking to hand over in an apparent swap arrangement.</p>\n<p>In an interview with Radio 103 FM, he confirmed that such a deal had been discussed with Britain last week but said an agreement had not materialised and was \"a thing of the past\".</p>\n<p>Israel's Haaretz newspaper put the amount of doses at about 1 million.</p>\n<p>\"We are negotiating with other countries,\" Levi told Radio 103 FM, without naming them. \"We are dealing with this day and night.\"</p>\n<p>He said the doses expire on July 31 and that any deal would have to win Pfizer's approval.</p>\n<p>A Pfizer spokesperson said the company \"is happy to discuss potential donations requests of the Pfizer/BioNTech COVID vaccine between governments on a case-by-case basis, particularly if this helps ensure the vaccine is used to protect people from this disease\".</p>\n<p>Last month the Palestinians rejected about a million doses from Israel, saying they were too close to their expiry date.</p>\n<p>Israel launched in December <a href=\"https://laohu8.com/S/AONE\">one</a> of the world's fastest vaccine drives and has since vaccinated nearly 90% of people over the age of 50, a group considered to be at the highest risk from the coronavirus.</p>\n<p>Overall, however, around a fifth of all eligible Israelis have not yet had the vaccine, according to health ministry data.</p>\n<p>With infections falling from more than 10,000 daily cases in January to single digits, Israel, with a population of 9.3 million, has dropped nearly all coronavirus curbs.</p>\n<p>But an uptick of cases that began in mid-June, attributed to the more contagious Delta variant, may bring some restrictions back, Levi said.</p>\n<p>Vaccination rates peaked in January and gradually fell until June, when 12 to 15-year-olds were made eligible for the jab. Delta's spread, particularly among schoolchildren, has spurred parents to get their children inoculated and the rate has increased five-fold since early June.</p>\n<p>Levi said Pfizer's vaccine was about 85-88% effective against the delta variant, a high figure but lower in comparison with its effectiveness against other strains.</p>\n<p>He based that figure on a British study as well as recent research by the health ministry. A ministry spokesperson did not immediately provide more details about the study.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Israel negotiating Pfizer surplus with other countries, official says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIsrael negotiating Pfizer surplus with other countries, official says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-05 08:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JERUSALEM, July 4 (Reuters) - Israel is in talks with other countries about a deal to unload its surplus of Pfizer/BioNtech</p>\n<p>COVID-19 vaccines, doses of which are due to expire by the end of the month, a health ministry official said on Sunday.</p>\n<p>Hezi Levi, the ministry's director-general, did not provide details about the number of doses Israel was looking to hand over in an apparent swap arrangement.</p>\n<p>In an interview with Radio 103 FM, he confirmed that such a deal had been discussed with Britain last week but said an agreement had not materialised and was \"a thing of the past\".</p>\n<p>Israel's Haaretz newspaper put the amount of doses at about 1 million.</p>\n<p>\"We are negotiating with other countries,\" Levi told Radio 103 FM, without naming them. \"We are dealing with this day and night.\"</p>\n<p>He said the doses expire on July 31 and that any deal would have to win Pfizer's approval.</p>\n<p>A Pfizer spokesperson said the company \"is happy to discuss potential donations requests of the Pfizer/BioNTech COVID vaccine between governments on a case-by-case basis, particularly if this helps ensure the vaccine is used to protect people from this disease\".</p>\n<p>Last month the Palestinians rejected about a million doses from Israel, saying they were too close to their expiry date.</p>\n<p>Israel launched in December <a href=\"https://laohu8.com/S/AONE\">one</a> of the world's fastest vaccine drives and has since vaccinated nearly 90% of people over the age of 50, a group considered to be at the highest risk from the coronavirus.</p>\n<p>Overall, however, around a fifth of all eligible Israelis have not yet had the vaccine, according to health ministry data.</p>\n<p>With infections falling from more than 10,000 daily cases in January to single digits, Israel, with a population of 9.3 million, has dropped nearly all coronavirus curbs.</p>\n<p>But an uptick of cases that began in mid-June, attributed to the more contagious Delta variant, may bring some restrictions back, Levi said.</p>\n<p>Vaccination rates peaked in January and gradually fell until June, when 12 to 15-year-olds were made eligible for the jab. Delta's spread, particularly among schoolchildren, has spurred parents to get their children inoculated and the rate has increased five-fold since early June.</p>\n<p>Levi said Pfizer's vaccine was about 85-88% effective against the delta variant, a high figure but lower in comparison with its effectiveness against other strains.</p>\n<p>He based that figure on a British study as well as recent research by the health ministry. A ministry spokesperson did not immediately provide more details about the study.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148388731","content_text":"JERUSALEM, July 4 (Reuters) - Israel is in talks with other countries about a deal to unload its surplus of Pfizer/BioNtech\nCOVID-19 vaccines, doses of which are due to expire by the end of the month, a health ministry official said on Sunday.\nHezi Levi, the ministry's director-general, did not provide details about the number of doses Israel was looking to hand over in an apparent swap arrangement.\nIn an interview with Radio 103 FM, he confirmed that such a deal had been discussed with Britain last week but said an agreement had not materialised and was \"a thing of the past\".\nIsrael's Haaretz newspaper put the amount of doses at about 1 million.\n\"We are negotiating with other countries,\" Levi told Radio 103 FM, without naming them. \"We are dealing with this day and night.\"\nHe said the doses expire on July 31 and that any deal would have to win Pfizer's approval.\nA Pfizer spokesperson said the company \"is happy to discuss potential donations requests of the Pfizer/BioNTech COVID vaccine between governments on a case-by-case basis, particularly if this helps ensure the vaccine is used to protect people from this disease\".\nLast month the Palestinians rejected about a million doses from Israel, saying they were too close to their expiry date.\nIsrael launched in December one of the world's fastest vaccine drives and has since vaccinated nearly 90% of people over the age of 50, a group considered to be at the highest risk from the coronavirus.\nOverall, however, around a fifth of all eligible Israelis have not yet had the vaccine, according to health ministry data.\nWith infections falling from more than 10,000 daily cases in January to single digits, Israel, with a population of 9.3 million, has dropped nearly all coronavirus curbs.\nBut an uptick of cases that began in mid-June, attributed to the more contagious Delta variant, may bring some restrictions back, Levi said.\nVaccination rates peaked in January and gradually fell until June, when 12 to 15-year-olds were made eligible for the jab. Delta's spread, particularly among schoolchildren, has spurred parents to get their children inoculated and the rate has increased five-fold since early June.\nLevi said Pfizer's vaccine was about 85-88% effective against the delta variant, a high figure but lower in comparison with its effectiveness against other strains.\nHe based that figure on a British study as well as recent research by the health ministry. A ministry spokesperson did not immediately provide more details about the study.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1728,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":155064434,"gmtCreate":1625364531328,"gmtModify":1703740763953,"author":{"id":"3574379344635374","authorId":"3574379344635374","name":"iawang","avatar":"https://community-static.tradeup.com/news/090ab974c3086142d05263cd704a81b6","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3574379344635374","idStr":"3574379344635374"},"themes":[],"htmlText":"Go go go go go!!!","listText":"Go go go go go!!!","text":"Go go go go go!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/155064434","repostId":"1165340887","repostType":4,"repost":{"id":"1165340887","kind":"news","pubTimestamp":1625257396,"share":"https://ttm.financial/m/news/1165340887?lang=&edition=fundamental","pubTime":"2021-07-03 04:23","market":"us","language":"en","title":"U.S. stocks sweep to fresh highs after strong jobs report","url":"https://stock-news.laohu8.com/highlight/detail?id=1165340887","media":"yahoo","summary":"Stocks rose Friday to record levels as investors digested a key print on the U.S. labor market recovery, which pointed to a faster pace of payroll gains than expected.The S&P 500 set another record high, kicking off the first sessions of the third quarter on a high note. The blue-chip index logged a seventh straight day of gains in its longest winning streak since August 2020. The Nasdaq also hit all-time intraday and closing highs, and the Dow gained to set its first record high since May 7. Sh","content":"<p>Stocks rose Friday to record levels as investors digested a key print on the U.S. labor market recovery, which pointed to a faster pace of payroll gains than expected.</p>\n<p>The S&amp;P 500 set another record high, kicking off the first sessions of the third quarter on a high note. The blue-chip index logged a seventh straight day of gains in its longest winning streak since August 2020. The Nasdaq also hit all-time intraday and closing highs, and the Dow gained to set its first record high since May 7. Shares of Tesla (TSLA) fluctuated before ending slightly higher after the electric car-maker's second-quarter deliveries hit a new record but still missed analysts' estimates, based on Bloomberg consensus data.</p>\n<p>Investorsconsidered the U.S. Labor Department's June jobs report, the central economic data point that came out this week. The print showed a stronger-than-anticipated acceleration in hiring, with non-farm payrolls rising by 850,000 for a sixth straight monthly gain. The unemployment rate, however, unexpectedly ticked up slightly to 5.9%.</p>\n<p>\"This is the 'Goldilocks report' that the market was looking for today. You had a nice print here of 850,000 jobs being added, wage pressure remaining — I wouldn't call them necessarily contained — but surprising here on the downside versus consensus estimates. So this is telling us right now that economic growth is continuing to accelerate here, the jobs market is continuing to heal,\" Emily Roland, co-chief investment strategist at John Hancock Investment Management, told Yahoo Finance. \"We're making progress here in terms of what the Fed has set out to do, which is in order to get unemployment get down, they're going to let inflation run a little bit hot here. Not too hot, not too cold — this is just what the market wants.\"</p>\n<p>Heading into the report, equities have been buoyed by a slew of strong economic data earlier this week, especially on the labor market.Private payrolls rose by a better-than-expected 692,000 in June,according to ADP, andweekly initial jobless claims improved more than expectedto the lowest level since March 2020. Still, other reports underscored the still-prevalent labor supply challenges impacting companies across industries, with the scarcity capping what has otherwise been a robust economic rebound.</p>\n<p>\"It's really the labor market supply that's putting the brake on hiring right now,\" Luke Tilley, chief economist for Wilmington Trust, told Yahoo Finance. \"But we're pretty optimistic, the market is pretty optimistic, and we think that's a big part of what's driving these indexes higher.\"</p>\n<p>Friday's jobs report will also give markets a suggestion as to the timing of the Federal Reserve's next monetary policy move. For now, the Fed has kept in place both of its key crisis-era policies, or quantitative easing and a near-zero benchmark interest rate. However, an especially strong jobs report and faster-than-expected print on wage growth could justify an earlier-than-currently-telegraphed shift by the central bank.</p>\n<p>“For the first time in years, I’m actually worried about a too hot number causing some kind of volatility or pullback in stocks. That’s because the Fed has signaled they are looking to taper QE,\" Tom Essaye, Sevens Report Research founder,told Yahoo Finance. \"And if we get a really, really strong jobs number and a hot wage number, then markets are going to start to say gee, are they going to taper QE maybe before November, or are they going to taper it more intensely than we thought and in a market that's frankly been very calm and a little bit complacent, that could cause volatility.\"</p>\n<p>Still, the Fed has suggested it would not react rashly to single reports, and has given itself leeway to adjust the timeline of its monetary policy pivots as more data comes in.</p>\n<p>\"I think everyone's counting on the Fed continuing really for the foreseeable future. So I don't see any big changes there coming before 2023,\" Octavio Marenzi, CEO and founder of Opimas,told Yahoo Finance.\"And even then the Fed has hedged its bets very significantly — they've basically said we might in 2023 raise interest rates twice, but then again we might not. So I think the smart money is betting things are going to keep on going, they're going to carry on with a very accommodative monetary policy.\"</p>\n<p>Even with the recent strength for stocks, market strategists say that uncertainty about the future of the Fed’s asset purchases and the upcoming earnings season could keep stocks from making major gains in the near term.</p>\n<p>“The market is still very much concerned about the Fed’s reaction function,” said Max Gokhman, head of asset allocation at Pacific Life Fund Advisors, adding that he thought there was still a lot of slack in the labor market.</p>\n<p>4:01 p.m. ET: Stocks close higher, S&amp;P 500 posts longest winning streak since August 2020</p>\n<p>Here's where markets closed out on Friday:</p>\n<ul>\n <li><p><b>S&amp;P 500 (^GSPC)</b>: +32.51 (+0.75%) to 4,352.45</p></li>\n <li><p><b>Dow (^DJI)</b>: +154.4 (+0.45%) to 34,787.93</p></li>\n <li><p><b>Nasdaq (^IXIC)</b>: +116.95 (+0.81%) to 14,639.33</p></li>\n</ul>","source":"lsy1584348713084","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stocks sweep to fresh highs after strong jobs report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stocks sweep to fresh highs after strong jobs report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-03 04:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/stock-market-news-live-updates-july-2-2021-221546079-221120965.html><strong>yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks rose Friday to record levels as investors digested a key print on the U.S. labor market recovery, which pointed to a faster pace of payroll gains than expected.\nThe S&P 500 set another record ...</p>\n\n<a href=\"https://finance.yahoo.com/news/stock-market-news-live-updates-july-2-2021-221546079-221120965.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://finance.yahoo.com/news/stock-market-news-live-updates-july-2-2021-221546079-221120965.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165340887","content_text":"Stocks rose Friday to record levels as investors digested a key print on the U.S. labor market recovery, which pointed to a faster pace of payroll gains than expected.\nThe S&P 500 set another record high, kicking off the first sessions of the third quarter on a high note. The blue-chip index logged a seventh straight day of gains in its longest winning streak since August 2020. The Nasdaq also hit all-time intraday and closing highs, and the Dow gained to set its first record high since May 7. Shares of Tesla (TSLA) fluctuated before ending slightly higher after the electric car-maker's second-quarter deliveries hit a new record but still missed analysts' estimates, based on Bloomberg consensus data.\nInvestorsconsidered the U.S. Labor Department's June jobs report, the central economic data point that came out this week. The print showed a stronger-than-anticipated acceleration in hiring, with non-farm payrolls rising by 850,000 for a sixth straight monthly gain. The unemployment rate, however, unexpectedly ticked up slightly to 5.9%.\n\"This is the 'Goldilocks report' that the market was looking for today. You had a nice print here of 850,000 jobs being added, wage pressure remaining — I wouldn't call them necessarily contained — but surprising here on the downside versus consensus estimates. So this is telling us right now that economic growth is continuing to accelerate here, the jobs market is continuing to heal,\" Emily Roland, co-chief investment strategist at John Hancock Investment Management, told Yahoo Finance. \"We're making progress here in terms of what the Fed has set out to do, which is in order to get unemployment get down, they're going to let inflation run a little bit hot here. Not too hot, not too cold — this is just what the market wants.\"\nHeading into the report, equities have been buoyed by a slew of strong economic data earlier this week, especially on the labor market.Private payrolls rose by a better-than-expected 692,000 in June,according to ADP, andweekly initial jobless claims improved more than expectedto the lowest level since March 2020. Still, other reports underscored the still-prevalent labor supply challenges impacting companies across industries, with the scarcity capping what has otherwise been a robust economic rebound.\n\"It's really the labor market supply that's putting the brake on hiring right now,\" Luke Tilley, chief economist for Wilmington Trust, told Yahoo Finance. \"But we're pretty optimistic, the market is pretty optimistic, and we think that's a big part of what's driving these indexes higher.\"\nFriday's jobs report will also give markets a suggestion as to the timing of the Federal Reserve's next monetary policy move. For now, the Fed has kept in place both of its key crisis-era policies, or quantitative easing and a near-zero benchmark interest rate. However, an especially strong jobs report and faster-than-expected print on wage growth could justify an earlier-than-currently-telegraphed shift by the central bank.\n“For the first time in years, I’m actually worried about a too hot number causing some kind of volatility or pullback in stocks. That’s because the Fed has signaled they are looking to taper QE,\" Tom Essaye, Sevens Report Research founder,told Yahoo Finance. \"And if we get a really, really strong jobs number and a hot wage number, then markets are going to start to say gee, are they going to taper QE maybe before November, or are they going to taper it more intensely than we thought and in a market that's frankly been very calm and a little bit complacent, that could cause volatility.\"\nStill, the Fed has suggested it would not react rashly to single reports, and has given itself leeway to adjust the timeline of its monetary policy pivots as more data comes in.\n\"I think everyone's counting on the Fed continuing really for the foreseeable future. So I don't see any big changes there coming before 2023,\" Octavio Marenzi, CEO and founder of Opimas,told Yahoo Finance.\"And even then the Fed has hedged its bets very significantly — they've basically said we might in 2023 raise interest rates twice, but then again we might not. So I think the smart money is betting things are going to keep on going, they're going to carry on with a very accommodative monetary policy.\"\nEven with the recent strength for stocks, market strategists say that uncertainty about the future of the Fed’s asset purchases and the upcoming earnings season could keep stocks from making major gains in the near term.\n“The market is still very much concerned about the Fed’s reaction function,” said Max Gokhman, head of asset allocation at Pacific Life Fund Advisors, adding that he thought there was still a lot of slack in the labor market.\n4:01 p.m. ET: Stocks close higher, S&P 500 posts longest winning streak since August 2020\nHere's where markets closed out on Friday:\n\nS&P 500 (^GSPC): +32.51 (+0.75%) to 4,352.45\nDow (^DJI): +154.4 (+0.45%) to 34,787.93\nNasdaq (^IXIC): +116.95 (+0.81%) to 14,639.33","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,"SPY":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":1995,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153501672,"gmtCreate":1625031024196,"gmtModify":1703850553589,"author":{"id":"3574379344635374","authorId":"3574379344635374","name":"iawang","avatar":"https://community-static.tradeup.com/news/090ab974c3086142d05263cd704a81b6","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3574379344635374","idStr":"3574379344635374"},"themes":[],"htmlText":"Commenting now","listText":"Commenting now","text":"Commenting now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153501672","repostId":"1100317118","repostType":4,"repost":{"id":"1100317118","kind":"news","pubTimestamp":1625030487,"share":"https://ttm.financial/m/news/1100317118?lang=&edition=fundamental","pubTime":"2021-06-30 13:21","market":"us","language":"en","title":"These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1100317118","media":"Motley Fool","summary":"The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The ind","content":"<p>The&nbsp;<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.</p>\n<p>The Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.<b>Cerevel Therapeutics Holdings</b>(NASDAQ:CERE)got a nice push higher, but investors in&nbsp;<b>Sensei Biotherapeutics</b>(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.</p>\n<p>Cerevel serves up an early win</p>\n<p>Shares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.</p>\n<p>Cerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.</p>\n<p>The company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.</p>\n<p>Cerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.</p>\n<p>A disappointment for Sensei</p>\n<p>Shares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.</p>\n<p>Sensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.</p>\n<p>Unfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.</p>\n<p>Sensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.</p>\n<p>The biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 13:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.\nThe Nasdaq is known ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc.","SNSE":"Sensei Biotherapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100317118","content_text":"The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.\nThe Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.Cerevel Therapeutics Holdings(NASDAQ:CERE)got a nice push higher, but investors in Sensei Biotherapeutics(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.\nCerevel serves up an early win\nShares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.\nCerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.\nThe company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.\nCerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.\nA disappointment for Sensei\nShares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.\nSensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.\nUnfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.\nSensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.\nThe biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.","news_type":1,"symbols_score_info":{"SNSE":0.9,"CERE":0.9}},"isVote":1,"tweetType":1,"viewCount":1823,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150549664,"gmtCreate":1624922837058,"gmtModify":1703847827748,"author":{"id":"3574379344635374","authorId":"3574379344635374","name":"iawang","avatar":"https://community-static.tradeup.com/news/090ab974c3086142d05263cd704a81b6","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3574379344635374","idStr":"3574379344635374"},"themes":[],"htmlText":"Oops hello there","listText":"Oops hello there","text":"Oops hello there","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/150549664","repostId":"2146836375","repostType":4,"isVote":1,"tweetType":1,"viewCount":2157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127502472,"gmtCreate":1624854399396,"gmtModify":1703846282925,"author":{"id":"3574379344635374","authorId":"3574379344635374","name":"iawang","avatar":"https://community-static.tradeup.com/news/090ab974c3086142d05263cd704a81b6","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3574379344635374","idStr":"3574379344635374"},"themes":[],"htmlText":"Gooooogle!!!","listText":"Gooooogle!!!","text":"Gooooogle!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127502472","repostId":"2146200677","repostType":4,"isVote":1,"tweetType":1,"viewCount":1902,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126406243,"gmtCreate":1624580530982,"gmtModify":1703840759906,"author":{"id":"3574379344635374","authorId":"3574379344635374","name":"iawang","avatar":"https://community-static.tradeup.com/news/090ab974c3086142d05263cd704a81b6","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3574379344635374","idStr":"3574379344635374"},"themes":[],"htmlText":"Here is a comment","listText":"Here is a comment","text":"Here is a comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/126406243","repostId":"1160256327","repostType":4,"isVote":1,"tweetType":1,"viewCount":2328,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121748154,"gmtCreate":1624493734678,"gmtModify":1703838174400,"author":{"id":"3574379344635374","authorId":"3574379344635374","name":"iawang","avatar":"https://community-static.tradeup.com/news/090ab974c3086142d05263cd704a81b6","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3574379344635374","idStr":"3574379344635374"},"themes":[],"htmlText":"Strong!!! Comment!!!","listText":"Strong!!! Comment!!!","text":"Strong!!! Comment!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/121748154","repostId":"1124226438","repostType":4,"isVote":1,"tweetType":1,"viewCount":1870,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120080848,"gmtCreate":1624288081784,"gmtModify":1703832619048,"author":{"id":"3574379344635374","authorId":"3574379344635374","name":"iawang","avatar":"https://community-static.tradeup.com/news/090ab974c3086142d05263cd704a81b6","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3574379344635374","idStr":"3574379344635374"},"themes":[],"htmlText":"Test comment here","listText":"Test comment here","text":"Test comment here","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/120080848","repostId":"1196408010","repostType":4,"isVote":1,"tweetType":1,"viewCount":1575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":true}